Nanjing Dalianshan Addiction Rehab Center
Nanjing, 210090, China
NCT Number: NCT04202926
A growing body of evidence suggests a wide range of brain areas including medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (DLPFC) and other subcortical regions, such as anterior cingulate cortex (ACC) are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial magnetic stimulation (rTMS) over dorsolateral prefrontal cortex reduces craving for meth dependences. Specifically, the H7 coil induces a magnetic field can target mPFC and ACC. In this study, the investigators investigated whether repeated dTMS intervention of medial prefrontal and cingulate cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Nanjing, 210090, China
The study will be conducted at the drug rehabilitation center in China. The whole procedure includes enrollment, pre-intervention evaluation, intervention (for 3 weeks, 5 times a week, 15 times in total), post-intervention evaluation and one month follow up evaluation.
In enrollment session, participants are recruited according to inclusion criteria.
In the pre-intervention evaluation, firstly, participants need complete a questionnaire to assess their demographic information, drug addiction history and drug abstinence. And then are assigned to either 10Hz group or sham group according to the counterbalance of their basic demographic and drug use information. Then, participants need complete craving, cognitive ability and electroencephalogram (EEG) assessment. For craving assessing, participants are shown a video of methamphetamine usage for 5 minutes, and then rated on the visual analogue scale (0 means completely undesired and 100 means extremely wanting) to report their craving for methamphetamine. For cognitive ability and EEG signal assessing, the whole process is conducted on the computer according to instructions.
In the intervention session, dTMS was administered using a TMS stimulator (Magstim, U.K.) equipped with a unique H-shaped coil design. The H-coil version used in this study was the H7 (Brainsway, Jerusalem, Israel). When placed 4-5 cm anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), the H7 coil stimulates the dorsal mPFC and ACC bilaterally. A participant's RMT was determined before the first treatment and at the beginning of each week by ascertaining the coil position that elicited the minimal involuntary contractions of the feet (three of six attempts). The 10Hz group received 10 Hz dTMS at 100% of RMT, with 3-second pulse and 17-second intervals, for a total of 50 trains and 1500 pulses per session. The sham group received treatment with identical technical parameters, which induced scalp sensations but without penetration of the electric field into the brain.
Post-intervention evaluation and one month follow up evaluation are the same as in pre-intervention evaluation.
To ensure study quality, some measures are taken as bellow:
Researchers and drug rehabilitation staff will work together in whole process and the data will be converted into electronic versions once finishing each evaluation.
In the intervention, patients, operators, and raters were blind to treatment condition. Each patient is assigned a magnetic card that determined the coil (real or sham) in the helmet and raters are not present while treatments are administered.
After each treatment times, any side effect from participant's report are recorded to assure the safety and feasibility.
Statistical analyses are performed using SPSS 21.0. The principal statistical analysis is performed using repeated-measures analysis of variance and regression analysis. All missing data will be recorded and marked.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Subjective craving (cue induced, 0-100 based VAS, craving scale) and drug cue-ERP (P300 etc. measured)
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
using cognitive tasks: stop-signal task
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
using cognitive tasks: n-back task
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
depression (Beck Depression inventory scale), high score means worse depression
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Anxiety (Beck anxiety inventory scale), higher score means worse anxiety
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
sleep status measurements (Pittsburgh Sleep Quality Index scale), higher score means worse sleep
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Impulsivity scale (The Barratt Impulsiveness Scale), higher score means higher impulsivity
Time frame: the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
resting EEG signal (Alpha, Beta, Theta, etc) measurement with 128 Channel EGI system
Time frame: every day after each intervention time for the 3 weeks intervention time period
Side effect scale, including headache, pricking, sleeplessness etc.
Shanghai Mental Health Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05162391
Methamphetamine-dependence, Rectal Chlamydia
Los Angeles, California, United States
View Trial DetailsNCT05128071
Behavior, Methamphetamine-dependence
Salt Lake City, Utah, United States
View Trial DetailsNCT03825536
HIV-1-infection, Inflammation
San Francisco, California, United States
View Trial DetailsNCT03341078
Inflammation, Methamphetamine-dependence
Portland, Oregon, United States
View Trial Details